LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out More(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:
Read more(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.
Read moreSyncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.
Read more(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.
Read moreSyncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.
Read more(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.
Read more(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.
Read more(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.
Read moreSyncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.
Read more(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.
Read moreSyncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read moreSyncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.
Read more(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".
Read more(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.
Read more